Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Share-based Compensation came in at $6.4 million in Q1 2026, up 118.32% year-on-year from $2.9 million in Q1 2025, and up 18.37% quarter-over-quarter from $5.4 million in Q4 2025.
Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026) Analysis & Trends
Oculis Holding AG's Share-based Compensation history runs 5 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 118.32% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $23.0 million, a 80.81% increase from a year earlier, with the FY2025 full-year figure at $19.4 million, up 74.03% from the prior year.
- Share-based Compensation grew to $6.4 million in Q1 2026 per OCS's latest filing, from $5.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.4 million in Q1 2026 and bottomed at $150513.2 in Q4 2022.
- The 5-year median for Share-based Compensation is $2.9 million (2024), against an average of $2.8 million.
- Across the five-year window, Share-based Compensation surged 733.86% in 2024 and soared 50.32% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $150513.2 in 2022, then soared by 680.47% to $1.2 million in 2023, then jumped by 176.17% to $3.2 million in 2024, then surged by 66.3% to $5.4 million in 2025, then grew by 18.37% to $6.4 million in 2026.
- Per Business Quant, the three latest OCS Share-based Compensation figures stand at $6.4 million (Q1 2026), $5.4 million (Q4 2025), and $5.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.39 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Dec 31, 2025 | 5.40 Mn |
| Dec 31, 2025 | 5.40 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |